Targeting metastatic cancer from the inside:
A new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ

ERLINDA M. GORDON, JOHN P. LEVY, REBECCA A. REED, W. NINA PETCHPUD, LIQIONG LIU, CARLAN B. WENDLER and FREDERICK L. HALL

1Oncology Research Unit, Epeius Biotechnologies Corporation, San Marino, CA 91108; 2Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

Received June 30, 2008; Accepted July 24, 2008

DOI: 10.3892/ijo_00000052

Abstract. The advent of pathotropic (disease-seeking) targeting technologies, combined with advanced gene delivery vectors, provides a unique opportunity for the systemic delivery of immunomodulatory cytokine genes to remote sites of cancer metastasis. When injected intravenously, such pathotropic nanoparticles seek out and accumulate selectively at sites of tumor invasion and neo-angiogenesis, resulting in enhanced gene delivery, and thus cytokine production, within the tumor nodules. Used in conjunction with a primary tumoricidal agent (e.g., Rexin-G) that exposes tumor neoantigens, the tumor-targeted immunotherapy vector is intended to promote the recruitment and activation of host immune cells into the metastatic site(s), thereby initiating cancer immunization in situ. In this study, we examine the feasibility of cytokine gene delivery to cancerous lesions in vivo using intravenously administered pathotropically targeted nanoparticles bearing the gene encoding granulocyte/macrophage colony-stimulating factor (GM-CSF; i.e., Reximmune-C). In vitro, transduction of target cancer cells with Reximmune-C resulted in the quantitative production of bioactive and immunoreactive GM-CSF protein. In tumor-bearing nude mice, intravenous infusions of Reximmune-C-induced GM-CSF production by transduced cancer cells and paracrine secretion of the cytokine within the tumor nodules, which promoted the recruitment of host mononuclear cells, including CD40+ B cells and CD86+ dendritic cells, into the tumors. With the first proofs of principle established in preclinical studies, we generated an optimized vector configuration for use in advanced clinical trial designs, and extended the feasibility studies to the clinic. Targeted delivery and localized expression of the GM-CSF transgene was confirmed in a patient with metastatic cancer, as was the recruitment of significant tumor-infiltrating lymphocytes (TILs). Taken together, these studies provide the first demonstrations of cytokine gene delivery to cancerous lesions following intravenous administration and extend the applications of cancer immunization in vivo.

Introduction

Immune modulation, in conjunction with tumor antigen presentation, represents a promising approach for optimizing the efficacy of cancer gene therapy protocols. In tumor vaccination strategies, cytokines such as granulocyte/macrophage colony-stimulating factor (GM-CSF) are employed to recruit antigen-presenting cells, including dendritic cells and macrophages, which result in the activation of tumor-infiltrating B and T lymphocytes against proteins expressed by cancer cells (1,2). GM-CSF, in particular, is known to induce the activation, migration, proliferation, and differentiation of a variety of immunologically active cell populations, thereby facilitating the development of both humoral- and cellular-mediated immunity (3-5). One promising vaccine approach involves the insertion of the GM-CSF gene into autologous cancer cells which are then irradiated and used for personalized immunization (6,7). These genetically engineered tumor cells produce the GM-CSF protein within the local environment of the cells, thereby activating the patients' own immune system to recognize these tumor cells and, eventually, to eradicate the cancer at other metastatic sites. Whether delivered as genetically engineered tumor cells or as a soluble GM-CSF protein, the cytokine must be present within the same compartment as the antigenic components (8). Indeed, the establishment of specific and long lasting antitumor immunity following vaccination with GM-CSF-transduced tumor cells requires the simultaneous presence of GM-CSF and tumor antigens at the vaccination site (9). However, in spite of the therapeutic potential demonstrated in animal models and early-phase clinical trials, the clinical development of these promising protocols has been limited by difficulties relating to the establishment of autologous tumor cell cultures (10) and/or the performance of individualized gene transfer procedures.
ex vivo (11). Moreover, it has been reported that ‘live’ GM-CSF-secreting tumor cell vaccines are considerably more effective than irradiated GM-CSF-secreting tumor cell vaccines in generating systemic antitumor immunity (12). Alternatively, localized delivery of GM-CSF by direct intratumoral injection, as well as paracrine secretion by genetically engineered cells, has been shown to be more effective in up-regulating lymph node sensitization when compared to systemic administration of the recombinant protein (13,14). Unfortunately, the majority of primary and metastatic lesions are not readily accessible for direct intratumoral injection, thus opportunities for effective anti-cancer vaccination remained out of reach.

An obvious approach to raising cytokine levels selectively within a cancerous lesion is the prospect of selective gene delivery, and a large number of gene delivery systems, or vectors, have been developed for such purposes (15,16). In this regard, the retroviral particle, rendered replication-incompetent by strategic molecular engineering, exhibits a set of virtues and inherent limitations that are particularly amenable to anti-cancer applications (10,16-18). Not only are these membrane-enveloped viral particles durable in terms of transit within the systemic circulation and efficient in terms of their gene delivery function, they are virtually stealth in terms of the immune system, thereby enabling repeated infusions to be administered without eliciting untoward and/or immediately inactivating immune responses (19,20). Retroviral particles based on the murine leukemic virus (MLV) exhibit a unique and purposeful limitation of infectivity that is restricted to dividing cells only, which serves to limit gene delivery to proliferative cancer cells and the proliferative vascular cells of a tumor’s blood supply, thus effectively sparing normal, non-dividing cells (21). In addition to these critical properties, the small size of these retroviral particles (100 nm) enhances the biodistribution and the histological penetrance, thus conducting the much-anticipated field of nanotechnology across the threshold of history and into the practical realm of medical delivery (16,22).

In this study, we will briefly review the bioengineering principles employed in the progressive evolution of the MLV retroviral vector, with an aim toward improving both the safety and the efficacy of this important gene delivery platform, as well as the efficiencies and economies of its biopharmaceutical production. While this platform has been employed as the vector of choice in a large number of clinical trials (23,24), well as the efficiencies and economies of its biopharmaceutical production. While this platform has been employed as the vector of choice in a large number of clinical trials (23,24), the pREX II retroviral expression vector is created by engineering a multiple cloning site (MSC) into the G1XSvNa vector (Genetic Therapy, Inc.) to produce G1(MCS)SvNa, which is then subjected to KpnI digestion followed by fusion of the KpnI fragment with the linearized pRV109 vector (37). The resulting pRexIE II retroviral expression vector is driven externally by the strong CMV promoter and internally (packaged components) by a hybrid MSV/MLV promoter at the 5’ LTR and a standard MLV LTR at the 3’ end. Bearing the strong CMV promoter and an SV40 ori, this plasmid is suitable for relatively high-titer vector production in 293T cells prepared by transient transfection protocols (33-34). The 0.44 kb cDNA encoding a GM-CSF factor, GenBank accession number NM 000758, flanked by PCR-derived restriction sites was cloned into the unique NotI (5’) and XhoI (3’) cloning sites of the pREX II vector. The 4th Generation (C-REX) and 5th Generation (Uber-REX) retroviral vectors were developed specifically for clinical use by Epeius Biotechnologies Corp. to eliminate all extraneous sequences that would otherwise be introduced by plasmid fusions and to incorporate greater efficiencies in vector packaging and production, while virtually eliminating
the incidence of inadvertent recombination. The advanced GM-CSF construct in Uber-REX (Reximmune-C-TNT) carries an additional gene, herpes simplex thymidine kinase (HSV-Tk), which serves as an additional safety feature (‘suicide gene’) by engendering cellular sensitivity to destruction by ganciclovir (GCV) or acyclovir (ACV).

**Production of pathotropic vectors bearing the GM-CSF gene.** High titer retroviral vectors were generated utilizing a transient three plasmid co-transfection system in which the packaging components gag-pol, the wild-type 4070A amphotropic (CAE) env or a chimeric MLV-based env construct bearing an auxiliary extracellular matrix targeting domain, and a retroviral packaging/expression vector bearing the respective GM-CSF construct were placed on separate plasmids, each containing a CMV promoter and an SV40 origin of replication (33,36). The tumor surveillance function of the pathology-targeted (pathotropic, disease-seeking) env protein results from the insertion of a matrix-binding peptide, derived from von Willebrand coagulation factor, into the primary structure of the MLV 4070A amphotropic envelope protein (CAE, 30). The resultant pathotropic vector exhibits a high-efficiency tumor-targeting feature, i.e., the ability to seek out and accumulate upon the exposed collagenous interfaces within the cancerous lesions (32-36). The resulting vectors are referred to as Mx-GM-CSF (or Reximmune-C), Mx-GM-CSF-Tk (Reximmune-C-TNT), CAE-GM-CSF (non-targeted control), and Mx-Null (targeted empty vector), to indicate the envelope arrayed on, and gene(s) encoded in, each vector.

**Determination of viral titers.** The infectious titer of retroviral vectors in murine NIH3T3 cells were determined as previously described, based on expression of the β-galactosidase or neomycin phosphotransferase resistance, neo r, gene (38). Viral titers are expressed as the number of nuclear β-galactosidase expressing colonies or G418 resistant colony forming units (CFU)/ml; however, the titer of Reximmune-C-TNT in the advanced Uber-REX vector system was determined as HAT-resistant CFU/ml; and Mx-GM-CSF-Tk (Reximmune-C-TNT), CAE-GM-CSF (non-targeted control), and Mx-Null (targeted empty vector), to indicate the envelope arrayed on, and gene(s) encoded in, each vector.

**GM-CSF production in transduced cell cultures.** To assess the production and secretion of GM-CSF, immunohistochemical staining of transduced cells was conducted using a polyclonal goat antibody raised against a peptide, N19, mapping at the amino terminus of human GM-CSF (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Moreover, human GM-CSF production was measured in culture medium collected over 48 h in Reximmune-C transduced NIH3T3 cells and plasmid-transfected 293T producer cell cultures using commercially available ELISA kits supplied by R&D Systems (Minneapolis, MN, USA). The production and secretion of GM-CSF in cultured cells was measured as concentration in pg/ml of culture medium and expressed as μg/10^6 cells/24 h. Bioactivity of the secreted GM-CSF protein was confirmed by cell proliferation assays in TF-1 human leukemic cells (39).

**In vivo gene transfer studies** in mice were conducted in compliance with a protocol approved by the University of Southern California Institution Animal Care and Use Committee. To evaluate the efficiency of targeted gene delivery based on the enforced expression of the GM-CSF transgene in vivo, subcutaneous tumor xenografts were established in ~25 gm athymic nu/nu mice by subcutaneous implantation of 1x10^7 MiaPaca2 human pancreatic cancer cells. When the tumors reached a size of ~20 mm^3, 200 μl of either the Reximmune-C vector, a non-targeted GM-CSF-expressing vector (CAE-GM-CSF), a targeted but empty vector (Mx-null), or phosphate-buffered saline (PBS, pH 7.4), was injected directly into the tail vein each day for a total of 10 days (2x10^6 CFU/dose; cumulative dose: 2x10^7 CFU for each vector). The mice were sacrificed by cervical dislocation one day after completion of the treatment cycle. Initial studies of Reximmune-C in human cancer patients were performed under Phase I safety protocols approved by the Philippine BFAD (36) and Asian Hospital and Medical Center’s Institutional Review Board. Surgical specimens obtained following treatment with Reximmune-C were fixed in formalin and embedded in paraffin for histological and immunohistochemical analysis.

**Immunostaining for human GM-CSF protein in tumor tissues.** For detection of the human GM-CSF expression in subcutaneous tumors, tumor tissues harvested at the end of the experiment were fixed in 10% formalin. Immunohistochemical staining for human GM-CSF was conducted in formalin-fixed tissue sections after antigen retrieval, using an affinity-purified goat polyclonal antibody raised against a peptide mapping at the amino terminus of human GM-CSF (N-19) supplied by Santa Cruz Biotechnology, Inc. After counterstaining with methyl green, the slides were examined for the presence of brownish-red immunostaining material indicating presence of the GM-CSF transgene in tumor sections. The efficiency of gene delivery (expressed as percentage) is determined by counting the number of GM-CSF-secreting cells (based on cytoplasmic GM-CSF immunoreactivity) in three high power fields per tumor nodule, divided by the total number of cells x100.

**Histochemical and immunohistochemical analysis of tumor-infiltrating host mononuclear cells in tumor nodules.** Histologic examination of hematoxylin-eosin stained tissue sections of vector-treated tumor-bearing mice were conducted using light microscopy. Purified rat monoclonal anti-mouse CD40 (Catalog #09661D) and CD86 (B7-2; Catalog #09271D) antibodies were supplied by PharMingen (USA). Immunostaining for CD40^+ B cells and CD86^+ dendritic cells in acetone-fixed frozen sections of tumor nodules was conducted using methods described previously (32). Immunohistochemical staining of GM-CSF expression in clinical specimens was performed by Dr XinHai An, at John’s Hopkins University, Baltimore, MD; histochemical staining for immunological cell determinants was conducted by Pathology Inc. (El Monte, CA).

**Vector toxicity studies.** To evaluate potential systemic toxicity, serum GM-CSF, serum chemistry levels and complete blood counts were measured in nude mice that received Reximmune-C
or PBS intravenously for 10 days. Likewise, blood chemistries and GM-GSF levels in patient serum were evaluated following the systemic administration of Reximmune-C.

**Results**

**Progressive development of retroviral expression vectors for clinical applications.** Moloney murine leukemia virus (Mo-MLV) is an RNA member of the mammalian C type Retrovirus Genera. It is composed of three main gene cassettes: gag (structural), pol (enzymatic), and envelope (cell recognition and entry). The gag gene is further subdivided into the structural genes encoding matrix (MA), capsid (CA) and nucleocapsid (NC), while the enzymatic pol gene is subdivided into three genes encoding protease (PR), reverse transcriptase (RT) and integrase (IN). The wild-type configuration of these gene cassettes is bounded by long-terminal repeat (LTR) sequences, that functions in gene transcription and as a template for replication and integration functions (Fig. 1A). Just downstream of the 5' LTR is a non-coding packaging sequence (Ψ), which is used to load the viral RNA genome into the structural icosahedral capsule of the retroviral particle. The 1st Generation, or split genome design, retroviral vectors developed for clinical gene therapy (40) placed a therapeutic transgene (Gene-Rx) on one plasmid, which contained the Ψ packaging sequence, while the gag-pol and envelope genes were not 'packaged,' as they were intended for use in combination with murine retroviral packaging cell lines. However, vector production was compromised and recombination events leading to the inadvertent production of infectious recombinant retrovirus (RCR) were common (Fig. 1B). Several 2nd Generation designs focused on improving the primary gene transfer plasmids (packaged transgene) by modifying either the LTR promoter sequences or the intrinsic RNA splicing mechanisms (41,42), yet these designs still relied on packaging cell lines for vector production (Fig. 1C).

The 3rd Generation vector designs (Fig. 1D) were developed to improve vector titers and eliminate problematic producer cells by creating plasmid fusions that placed strong exogenous promoters upstream of the 'packaged' retroviral elements (37), and by incorporating SV40 origins of replication into the plasmid backbones, which raised vector titers while replacing stable packaging cell lines with transient co-transfection protocols, followed by significant genetic improvements in clinical designs (E, F) that focused on vector production, gene expression, and safety considerations. See text for specific references.
FDA-approved clinical design (Epeius C-Rex, Fig. 1E) which eliminated cumbersome elements of previous plasmid fusions and placed minimal promoter sequences in an optimal configuration for high performance, thereby yielding appreciably higher titers (35,43). While the performance of these progressively improved 3rd, and 4th Generation retroviral vectors have not generated any detectable RCR vector production in the absence of problematic murine producer cell lines, all of these modern designs retained significant overlaps in homologous sequences that, however unlikely, could possibly recombine in a series of three independent events (42). Thus, the problem of a so-called triple-crossover event that could theoretically generate RCR still loomed over large-scale vector production, necessitating the development of a further-refined 5th Generation vector design by Levy et al, of Epeius Biotechnologies (Fig. 1F). Virtually eliminating overlapping sequences, while generating ultra-high vector titers (1x10^10) and retaining the optimized functional elements for efficient packaging, splicing, and gene expression, the 5th Generation Uber-Rex series of vectors represents the current state-of-the-art in clinical vector design.

Characterization of GM-CSF transgene expression in cultured cells. Gene transfer studies performed in vitro showed that human GM-CSF was highly expressed in and secreted by both human 293T producer cell and murine NIH3T3 cell cultures. At an MOI of 100, immunoreactive human GM-CSF was noted in >75% of plasmid-transfected 293T cells and 40-50% of vector-transduced NIH3T3 cells (n=3 each group), with human cell lines generally displaying higher levels of infectivity. For Reximmune-C in C-Rex vectors, GM-CSF production was ~100 ng/10^6 cells/24 h in plasmid-transfected 293T cell cultures, and 30 ng/10^6 cells/24 h in transduced NIH3T3 cell cultures (Fig. 2), as determined by dilution of the cell culture supernatants and comparison with a purified human GM-CSF standard. Under these standardized conditions, the Uber-Rex vector bearing both the GM-CSF gene and the HSVtk gene (i.e., Reximmune-C-TNT) yielded an average productivity of 50 ng/10^6 cells/24 h (human fibroblastic HT1080 cells), and the bioactivity of the secreted GM-CSF protein was confirmed by bioassay. As shown in Fig. 2C, the addition of either ganciclovir (GCV) or acyclovir (ACV) to the culture medium of transduced A375 human melanoma cells resulted in a dose-dependent elimination of the cells with an IC_{50} of 0.03 μm for GCV and 3.0 μm for ACV, respectively.

Pathotropic targeting, GM-CSF expression, and immune modulation in tumor xenografts. We previously reported on the high level transduction (35-50%) of human tumor cancer xenografts in mice following intravenous infusion of matrix-targeted vectors bearing discernable marker genes (32,33). As shown in Fig. 3, the vector accumulates rapidly in tumorous tissues within minutes of infusion into the general circulation, spreading into the interstices of the tumor nodule and transducing resident tumor cells with high efficiency. As seen in Fig. 3C, this physiological ‘surveillance’ property of the targeted vector is entirely dependent on the gain-of-function provided by the tumor-targeting moiety. Consistent with the high levels of cell transduction observed within the tumor nodules, immunohistochemical analysis revealed high-level expression of human GM-CSF protein in resident cells (~35%) within the tumor xenografts of Reximmune-C vector-treated mice (Fig. 4B and C), compared to <1% in the non-targeted GM-CSF vector-treated and targeted null vector-treated mice (Fig. 4A). These findings demonstrate the feasibility of delivering cytokine genes to distant or inaccessible tumors by intravenous injection of pathotropically-targeted vectors such as Reximmune-C.

Further, extensive infiltration of host mononuclear cells was noted in the tumor nodules of Reximmune-C-treated mice (Fig. 5B and D) compared to minimal mononuclear infiltration observed with a non-targeted GM-CSF vector, a Mx-targeted-but-null vector-, or PBS-control treated animals (Fig. 5A and C). Within the tumor xenografts, the tumor infiltrating lymphocyte (TIL) to tumor cell (T) ratio was as high as 20:1 in Reximmune-C-treated mice compared to 1:90 in non-targeted GM-CSF vector-treated and targeted null vector-treated mice (Fig. 4A). These findings demonstrate the feasibility of delivering cytokine genes to distant or inaccessible tumors by intravenous injection of pathotropically-targeted vectors such as Reximmune-C.
Figure 3. Biodistribution of pathotropic nanoparticles into metastatic lesions in nude mice. Preclinical models of metastatic pancreatic cancer, wherein human tumor xenografts of MiaPaca2 cells were implanted into the flanks of athymic nude mice, provided a unique view of the penetrance and over-all efficiency of the tumor-targeted vectors. When retroviral vectors bearing a β-galactosidase marker gene are infused into the tail vein of tumor-bearing mice, these vectors traverse the heart and lungs and the heart again, only to leave the vascular system (A) and accumulate in the cancerous tissues (B and D) within 60 min of infusion (as determined by specific immunocytochemical staining), displaying a physiological surveillance function that is entirely dependent on the targeting domain (C). Spreading throughout the tumors like moisture in a sponge, the vectors selectively deliver their genetic payloads to proliferative tumor cells (E) with high efficiency. (F), represents an immunocytochemical control.

Figure 4. GM-CSF production in tumors of Reximmune-C vector-treated mice. Subcutaneous tumor xenografts were established in athymic nu/nu mice by subcutaneous implantation of 1x10^7 MiaPaca2 cells. When the tumors reached a size of ~20 mm^3, 200 μl of either the Reximmune-C vector (B-D) or a non-targeted-GM-CSF control vector (A) was injected directly into the tail vein daily for 10 days (cumulative vector dose: 2x10^7 CFU for each vector). The mice were sacrificed one day after completion of the treatment, and the harvested tumor sections were immunostained for presence of the GM-CSF transgene using a goat polyclonal anti-GM-CSF antibody. Immunoreactive GM-CSF protein was noted in ~35% of cells throughout the tumor nodules of Reximmune-C vector-treated mice (B and C) compared to <1% in the non-targeted CAE-GM-CSF vector-treated mice (A). (D), represents a Reximmune-C-treated nodule without primary antibody, which served as an immunocytochemical control.
T cells, these findings indicate successful recruitment of available host antigen-presenting cells and humoral antibody-producing B cells into the tumor nodules by the immunomodulatory action of the GM-CSF protein secreted by the very cancer cells targeted by Reximmune-C in this preclinical model of metastatic cancer.

Since the systemic administration of recombinant human GM-CSF protein at therapeutic levels can be associated
with toxic systemic side effects, we measured the levels of human GM-CSF in the sera of mice treated with high-dose Reximmune-C for 10 days. Human GM-CSF was not detected (<10 pg/ml detection limits) in sera of 4 mice treated with the highest dose of Reximmune-C, and serum chemistry levels and complete blood counts were within normal limits. These findings indicate that intravenous administration of Reximmune-C produces a localized expression of GM-CSF in effective local concentrations, and thus would not have the undesirable systemic toxicities that frequently limit the clinical utility of commercially available recombinant human GM-CSF.

Deployment of Reximmune-C in pilot clinical studies. With the approval of Rexin-G for clinical use in treating all solid tumors that are refractory to standard chemotherapy in the Philippines, came the possibility of examining the safety and potential efficacy of sequential targeted gene delivery in clinical cases of otherwise intractable cancer. Thus we began a Phase I Feasibility Study of sequential targeted gene delivery - using both Rexin-G and Reximmune-C - two tumor-targeted gene delivery vectors designed to deliver its respective genetic payload to metastatic cancer cells. Rexin-G and Reximmune-C were prepared and delivered as separate pathotropic nanoparticles bearing a cytotoxic cyclin G1 gene or a GM-CSF gene, respectively. As demonstrated in Fig. 3, when injected intravenously, these targeted vectors seek out and accumulate in cancerous lesions, thus increasing the effective local concentrations of the nanoparticles within the tumors.

The working hypothesis behind this two-stage approach to cancer management predicts that a strategic and individualized vaccination of a patient against his/her own cancer can be achieved by combining i) the targeted vector bearing a potent cytotoxic construct, Rexin-G, with ii) a targeted vector bearing an immune activating gene, Reximmune-C. The tumor-targeted Rexin-G is given first to kill the cancer cells and thus expose neoantigens within the tumor nodules, followed by Reximmune-C to recruit the body's immune cells to the same cancer compartments, thereby prompting recognition of the tumor neoantigens in situ and thereby promoting a long-lasting anti-tumor immunity. If successful, the strategy would be of considerable utility in cancer patients who have received clinical benefits from Rexin-G in the form of tumor control, but are still at risk of recurrence.

The purpose of the Phase I clinical study was to evaluate the overall safety/toxicity and therapeutic potential of this sequential regimen, using i.v. infusions of Rexin-G followed by pulses of Reximmune-C, in an effort to achieve a personalized cancer vaccination in vivo in patients with chemoresistant solid tumors. The initial results of the first seven cancer patients in the Phase I study were recently presented at a 2008 Meeting of the American Society of Clinical Oncology, (44) and a detailed report on the clinical data will be presented elsewhere (Cornelio et al, unpublished data). Meanwhile, we report herein on the biotechnological proofs-of-principle that have been demonstrated to date. As shown in Fig. 7, sequential infusions of Rexin-G followed by Reximmune-C in a patient with metastatic non-small cell lung cancer (NSCLC) revealed extensive apoptosis and necrosis of cancer cells in the tumorous organ, and recruitment of significant amounts of immune infiltrates (Fig. 7A). Expression of the GM-CSF transgene by cancer cells within the tumor-infiltrated adrenal gland was confirmed by immunohistochemical staining of resected tumor sections (Fig. 7B), as was the presence of a host of tumor infiltrating lymphocytes (TILs), including CD68+ macrophages and CD8+ killer T cells (Fig. 7C). Importantly, GM-CSF protein was not detected in serum samples either during or after treatment with Reximmune-C, indicating that the immunostimulatory influence of GM-CSF transgene expression was limited and that the intended cancer vaccination was highly localized, as designed.

Discussion

Retroviral expression vectors display an array of virtues and limitations that make these gene delivery vehicles an ideal...
choice for prospective cancer gene therapy applications (10,22). The modern vectors derived from the MoMLV vector core are largely ‘stealth’ in terms of rapid immune inactivation, thereby enabling repeated vector infusions over extended periods of time in an effort aimed at sustained tumor control (34-36). The progressive development of clinical grade vectors (Fig. 1) served to enhance this property of ‘stealth’ by transitioning to human producer cells (19,20,37), while improving vector production, gene expression, and titers, and virtually eliminating concerns over inadvertent recombination events that might yield untoward RCR infectivity (41-43).

A further limitation of this class of C-type retrovirus is the restriction of the therapeutic gene expression to actively dividing cells only, which serves to focus the functional gene delivery to proliferative cancer cells and their associated neovasculature, while sparing normal cells and tissues. This same set of virtues and intrinsic limitations is applicable to the strategic delivery of immunomodulatory cytokine genes to sites of metastatic cancer to achieve a personalized cancer vaccination.

The prospects of selective gene delivery to sites of metastatic cancer is both enabled and exemplified by the development of pathotropic targeting technologies embodied in Rexin-G (29,30,32,33), and which have now been extended to the targeted cancer vaccine, Reximmune-C.

The major advantages of precise tumor-targeted gene delivery are two-fold: first, it provides a simple method (intravenous infusion) of delivering therapeutic genes efficiently to surgically inaccessible sites such as metastatic tumors (34-36). Second, the preferential vector accumulation and integration at specific tumor loci reduces the number of vector particles available for biodistribution to non-target organs, while limiting paracrine cytokine secretion to specific tumor sites would tend to minimize the incidence of systemic toxicity.

In this study, we describe the development, construction, characterization, preclinical evaluation, and clinical validation of Reximmune-C, a tumor-targeted retroviral vector designed to deliver GM-CSF selectively to sites of metastatic cancer for the purposes of anti-cancer vaccination. Evaluation of the expression and secretion of the GM-CSF transgene in various human cancer cells in vitro, provides an estimate of ~50 ng/10^6 cells/24 h (which is well within the range of productivities reported for mammalian expression systems) which can be used as an approximation to predict the pharmacological productivity in vivo (see below). In a series of preclinical studies of metastatic cancer, the selectivity, tissue penetrance, and over-all efficiency of pathotropic tumor targeting was demonstrated (Fig. 3); the expression/secretion of GM-CSF transgene/protein within the remote tumor nodules was confirmed (Fig. 4); the subsequent recruitment of host mononuclear cells into tumor nodules was documented (Fig. 5); and characterization of the phenotype of the activated tumor infiltrating lymphocytes, which included professional antigen presenting dendritic cells, was performed (Fig. 6). These predictable immunostimulatory influences of GM-CSF were all achieved at the local level, i.e., metastatic sites, while the circulating blood levels of GM-CSF in the Reximmune-C-treated animals remained undetectable. Thus, the critical proofs-of-principle that validate the performance of the gene targeting system, the physiological effects of the cytokine, and the general safety of the approach all encourage clinical development of Reximmune-C for cancer immunotherapy.

Virtually all of the active principles established in preclinical studies were recently validated in the crucible of clinical medicine (44). In a Phase I safety study in which the tumoricidal Rexin-G was used to provide abundant tumor neoantigens, while the Reximmune-C was employed to deliver the GM-CSF bearing Reximmune-C, both the partial destruction of the tumors and the localized secretion of the immunostimulatory cytokine was confirmed, as was the recruitment of a significant amount of immune infiltrate. However, unlike the nude mouse, which lacks a complement of functional T cells, the tumors parenal gland of the patient with metastatic NSCLC was infiltrated by a spectrum of TILs which included CD8+ killer T cells (Fig. 7). Here again, the immunostimulatory effects were observable within the microenvironment of the metastatic tumor nodule, while the blood levels of GM-CSF remained basal.

At this point, several additional points-to-consider are worthy of discussion. First is the need to further ascertain the optimal sequence and timing of the vaccination pulse in relation to the presentation of neoantigens in the form of tumor debris, since there seems to be a significant difference in the type of anti-cancer immunity, cellular versus humoral, that is generated under these different scenarios (3-5,8,9). And until such refinements can be integrated with certainty into the clinical protocols, one would continue to utilize a ‘sandwich’ approach in which Rexin-G is administered both before and after the vaccination pulse. The next point-to-consider concerns the recommended dosage of immunomodulatory Reximmune-C, which is presumably far less than the doses of cytotoxic Rexin-G needed to bring chemoresistant metastatic cancer under control (34-36). If we can make some tentative approximations from the preclinical and clinical data currently at hand, and the Calculus of Parity (performance coefficient of the targeting system) obtained from a variety of clinical cases (35), we can estimate a starting point of ~1 ml of Reximmune-C for future clinical protocols at a titer of 1x10^10 U/ml, as follows:

\[
D = \frac{P \times T \times I_v}{\Phi}
\]

where daily dose (D) in μg/day equals production (P) in ng/10^6 cells/24 h multiplied by vector titer (T) in gene transfer units/ml, multiplied by infusion vol (I_v) in ml, divided by the performance coefficient (Φ) in gene transfer units/cell. For example:

\[
Dose = \frac{50 \text{ (ng/10}^6 \text{ cells/24 h) } \times 10^{10} \text{ (U/ml) } \times 1 \text{ (ml)}}{100 \text{ (U/cell)}} = 5 \mu g/24 \text{ h (per 1 ml of Reximmune-C vaccine)}
\]

This dose of Reximmune-C, while shown to be effective at the level of the metastatic cancer nodule, is a fraction of the doses of GM-CSF that are generally given systemically as an adjuvant in cancer immunotherapy protocols, which ranges from 80 μg/day for 4 consecutive days (45) to 125 μg/day for...
14 consecutive days (46) to 250 μg/day for 5 consecutive days (47).

In an effort to provide clinical oncologists with the most robust and advanced molecular genetic tools possible, further refinement of the REXimmune-C vector to include a ‘fail-safe’ or OFF switch, in terms of sensitivity to the herpetic prodrugs Ganciclovir or Acyclovir, was accomplished by the addition of the HSVtk gene to the GM-CSF expression cassette, thereby generating the REXimmune-C-TNT vector, which establishes a new state-of-the-art. The development of this new ‘fail-safe’ vector provides an unprecedented precision in terms of regulating cytokine expression by pharmacological means (i.e., limiting the number of days of cytokine production following GM-CSF transgene delivery), which will enable repeated personalized vaccinations to be given with a controllable margin of safety. Taken together, this new generation of retroviral vectors enables clinical applications that reach beyond the field of the most gifted surgeon, beyond the reach of the finest of catheters, to the very fabric of nature to bring about the control of metastatic disease and to encourage the patient’s natural immune responses that work in concert with the clinician towards that end.

Acknowledgements

This paper is dedicated to those who are no longer present, yet in whose memory and honor we continue to strive. The authors are grateful to the clinical investigators of the Phase I/II study, Gerardo H. Cornelio, Conrado C. Lorenzo III, Francisco F. Lopez, and to Evangeline Camunayan, Antonette Balais, and Alicia B. De Guzman for technical assistance. This work was supported by Epeius Biotechnologies Corporation, San Marino, CA, USA.

References


